🔓 Unlock the full profile of Peter Smith (Remix Therapeutics), including verified contact details, financial insights, and professional associations.
See Peter Smith Full ProfileBelow are the ✅ Verified Contact Details to help you connect directly:
Email: pet*****@rem******.com
Mobile: 81816*****
Estimated Net Worth 💰 : ₹0 – ₹500+ Cr (approx. $0 – $60M)
Key Insights You Should Know About This Individual
- Peter Smith is the Co-Founder, President, and CEO of Remix Therapeutics, a biotechnology company focused on RNA-targeted therapeutics, established in 2018.
- Smith began their leadership role at Remix Therapeutics in August 2021, overseeing the development of innovative treatments targeting RNA biology.
- In addition to being CEO, Smith co-founded Remix Therapeutics and previously served as the Chief Scientific Officer from August 2019, driving research and development strategies.
- During tenure at Remix Therapeutics, the company has made significant strides in advancing its proprietary platform for RNA modulation, which could transform therapeutic approaches for various diseases.
- Smith is also actively involved on the Board of Directors for Ryvu Therapeutics as of June 2023, contributing expertise in the biotech sector.
- Prior experience includes serving as Chief Scientific Officer at H3 Biomedicine from January 2011 to January 2018, where strategic leadership in drug discovery and development was provided.
- Smith's early career involved a notable position as Senior Scientist II at Millennium Pharmaceuticals from January 2004 to November 2011, contributing to foundational pharmaceuticals research.
- As an Atlas Advisor since January 2018, Smith provides mentorship and strategic guidance to emerging biotech companies under the Atlas Venture umbrella.
- Remix Therapeutics has seen a steady growth in its workforce, with a 7.58% increase over the last six months, indicating positive momentum under Smith’s leadership.
- Smith champions a collaborative culture at Remix Therapeutics, aiming to foster innovation and inclusive growth in the biotechnology field.